Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation

British Journal of Surgery

Volumn 102, Issue 10, 2015, Pages 1250-1257

  Orci, L A ^a,b   Berney, T ^a,b   Majno, P E ^a,b   Lacotte, S ^a   Oldani, G ^a,b   Morel, P ^a,b   Mentha, G ^a,b   Toso, C ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA, HEPATOCELLULAR; CONTROLLED STUDY; DONOR; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SWITZERLAND; TIME; TRENDS; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; SWITZERLAND; TIME FACTORS; TISSUE DONORS; WAITING LISTS;

EID: 84939271122     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9868     Document Type: Article

References (33)

1. Vitale A, Boccagni P, Kertusha X, Zanus G, D'Amico F, Lodo E, et al,. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? Transplant Proc 2012; 44: 1989-1991.
2. Toso C, Meerberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, et al,. Total tumor volume and alpha fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 2015; [Epub ahead of print].
3. Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, et al,. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107-1115.
4. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al,. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al,. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
6. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY,. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013; 14: 1343-1353.
7. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al,. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-994.
8. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G,. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 2013; 23: 522-532.
9. Hamady ZZ, Rees M, Welsh FK, Toogood GJ, Prasad KR, John TK, et al,. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases. Br J Surg 2013; 100: 820-826.
10. Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, et al,. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 2011; 53: 1570-1579.
11. Clavien PA, Petrowsky H, DeOliveira ML, Graf R,. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545-1559.
12. Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, et al,. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases-activation of cell invasion and migration pathways. Liver Transpl 2007; 13: 1669-1677.
13. Nicoud IB, Jones CM, Pierce JM, Earl TM, Matrisian LM, Chari RS, et al,. Warm hepatic ischemia-reperfusion promotes growth of colorectal carcinoma micrometastases in mouse liver via matrix metalloproteinase-9 induction. Cancer Res 2007; 67: 2720-2728.
14. van der Bilt JD, Soeters ME, Duyverman AM, Nijkamp MW, Witteveen PO, van Diest PJ, et al,. Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Am J Pathol 2007; 170: 1379-1388.
15. Jay C, Ladner D, Wang E, Lyuksemburg V, Kang R, Chang Y, et al,. A comprehensive risk assessment of mortality following donation after cardiac death liver transplant-an analysis of the national registry. J Hepatol 2011; 55: 808-813.
16. Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, et al,. Ischemia time impacts recurrence of hepatocellular carcinoma following liver transplantation. Hepatology 2015; 61: 895-904.
17. Samoylova ML, Dodge JL, Vittinghoff E, Yao FY, Roberts JP,. Validating posttransplant hepatocellular carcinoma recurrence data in the united network for organ sharing database. Liver Transpl 2013; 19: 1318-1323.
18. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al,. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transpl 2006; 6: 783-790.
19. Gray RJ,. A Class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
20. Schoenfeld DA,. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69: 239-241.
21. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
22. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ,. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
23. Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, et al,. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci 2012; 57: 806-812.
24. Vagefi PA, Dodge JL, Yao FY, Roberts JP,. The potential role of the donor in hepatocellular carcinoma recurrence following liver transplantation. Liver Transpl 2015; 21: 187-194.
25. Viganò L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L,. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 2013; 258: 731-740.
26. van der Bilt JD, Kranenburg O, Borren A, van Hillegersberg R, Borel Rinkes IH,. Ageing and hepatic steatosis exacerbate ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Ann Surg Oncol 2008; 15: 1392-1398.
27. Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, et al,. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford) 2013; 15: 504-510.
28. Fromenty B, Berson A, Pessayre D,. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997; 26 (Suppl 1): 13-22.
29. Hribal ML, Procopio T, Petta S, Sciacqua A, Grimaudo S, Pipitone RM, et al,. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2013; 98: E304-E308.
30. Vansaun MN, Mendonsa AM, Lee Gorden D,. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalcoholic fatty liver disease. PloS One 2013; 8: e73054.
31. Peyrou M, Bourgoin L, Foti M,. PTEN in liver diseases and cancer. World J Gastroenterol 2010; 16: 4627-4633.
32. Oldani G, Crowe LA, Orci LA, Slits F, Rubbia-Brandt L, de Vito C, et al,. Pre-retrieval reperfusion decreases cancer recurrence after rat ischemic liver graft transplantation. J Hepatol 2014; 61: 278-285.
33. Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, Grossi G, et al,. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol 2013; 59: 59-66.